MDxHealth (NASDAQ:MDXH) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of MDxHealth (NASDAQ:MDXH – Free Report) to a hold rating in a report issued on Saturday.

Separately, Craig Hallum started coverage on MDxHealth in a research report on Thursday, July 17th. They issued a “buy” rating and a $8.00 target price for the company. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $7.00.

View Our Latest Analysis on MDXH

MDxHealth Price Performance

Shares of NASDAQ:MDXH opened at $3.55 on Friday. MDxHealth has a fifty-two week low of $1.35 and a fifty-two week high of $3.81. The business has a 50-day simple moving average of $2.61 and a two-hundred day simple moving average of $2.06. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.22 and a current ratio of 1.31. The firm has a market cap of $167.88 million, a price-to-earnings ratio of -4.03 and a beta of 1.48.

MDxHealth (NASDAQ:MDXH – Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%.The business had revenue of $26.60 million during the quarter, compared to analysts’ expectations of $26.60 million. MDxHealth has set its Q2 2025 guidance at -0.150–0.150 EPS. On average, analysts expect that MDxHealth will post -1.15 earnings per share for the current year.

Institutional Investors Weigh In On MDxHealth

Large investors have recently made changes to their positions in the company. Geode Capital Management LLC bought a new stake in shares of MDxHealth during the 4th quarter valued at about $25,000. Castleview Partners LLC bought a new stake in shares of MDxHealth during the 1st quarter valued at about $48,000. Delta Investment Management LLC bought a new stake in shares of MDxHealth during the 4th quarter valued at about $81,000. FreeGulliver LLC bought a new stake in shares of MDxHealth during the 2nd quarter valued at about $273,000. Finally, Renaissance Technologies LLC grew its stake in shares of MDxHealth by 715.2% during the 4th quarter. Renaissance Technologies LLC now owns 123,100 shares of the company’s stock valued at $292,000 after purchasing an additional 108,000 shares during the period.

About MDxHealth

(Get Free Report)

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.

Featured Articles